Trial
NCT03490162
Safety and Pharmacokinetics Study of DM1157 to Treat Malaria
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators
—
Condition
Malaria
Intervention
DM1157
Why stopped
There was toxicity in higher dose groups and a therapeutic dose level was not found in lower dose groups.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-07-23